Search
MRK-003
go.drugbank.com/drugs/DB17015ExperimentalMRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682]
ICG-136
go.drugbank.com/drugs/DB17343ExperimentalICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics. It was investigated for the treatment of acute myeloid leukemia.
LuLym-T
go.drugbank.com/drugs/DB17405ExperimentalDeveloped by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.
Mozafancogene autotemcel
go.drugbank.com/drugs/DB17723InvestigationalRP-L102 is a lentiviral vector carrying the Fanconi Anemia-A (FANCA) gene currently being developed by Rocket Pharmaceuticals for the treatment of Fanconi anemia type A
Thymol
go.drugbank.com/drugs/DB02513ApprovedInvestigationalA phenol obtained from thyme oil or other volatile oils. It is used as a stabilizer in pharmaceutic preparations. It has been used for its antiseptic, antibacterial, and antifungal actions, and was formerly used as a vermifuge. (Dorland,...
Mixtures: Neo Medicated Plaster with Ginger and Lemongrass Oil AromaFeprazone
go.drugbank.com/drugs/DB13364ExperimentalCategories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSPerflubron
go.drugbank.com/drugs/DB05791InvestigationalPerflubron (Oxygent) is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.
ISO-1 F-18
go.drugbank.com/drugs/DB14900InvestigationalISO-1 F-18 is under investigation in clinical trial NCT00968656 (Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1).
Digoxigenin
go.drugbank.com/drugs/DB03671ExperimentalCan be obtained by hydrolysis of digoxin or from Digitalis orientalis L. and Digitalis lanata Ehrh.
Nezastomig
go.drugbank.com/drugs/DB19061InvestigationalNezastomig is under investigation in clinical trial NCT06085664 (A Pilot Presurgical Trial of REGN5678 (Anti-psma X CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy